AU2238395A - Haptenated peptides and uses thereof - Google Patents

Haptenated peptides and uses thereof

Info

Publication number
AU2238395A
AU2238395A AU22383/95A AU2238395A AU2238395A AU 2238395 A AU2238395 A AU 2238395A AU 22383/95 A AU22383/95 A AU 22383/95A AU 2238395 A AU2238395 A AU 2238395A AU 2238395 A AU2238395 A AU 2238395A
Authority
AU
Australia
Prior art keywords
seq
peptide
ala
pdc
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22383/95A
Other languages
English (en)
Inventor
Malcolm L. Gefter
Cohava Gelber
Julia L Greenstein
Charles J Hackett
Kurt Jeff Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Publication of AU2238395A publication Critical patent/AU2238395A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU22383/95A 1994-04-01 1995-03-30 Haptenated peptides and uses thereof Abandoned AU2238395A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US383645 1982-06-01
US22220694A 1994-04-01 1994-04-01
US222206 1994-04-01
US38364595A 1995-02-06 1995-02-06
PCT/US1995/004121 WO1995026980A2 (fr) 1994-04-01 1995-03-30 Peptides haptines et leurs utilisations

Publications (1)

Publication Number Publication Date
AU2238395A true AU2238395A (en) 1995-10-23

Family

ID=26916551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22383/95A Abandoned AU2238395A (en) 1994-04-01 1995-03-30 Haptenated peptides and uses thereof

Country Status (3)

Country Link
AU (1) AU2238395A (fr)
CA (1) CA2186873A1 (fr)
WO (1) WO1995026980A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022306A1 (fr) * 1995-01-16 1996-07-25 Northern Sydney Area Health Service Nouveau peptide
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
GB2349463B (en) 1996-03-21 2001-01-10 Circassia Ltd Cryptic peptides and method for their identification
JP2000512277A (ja) 1996-06-07 2000-09-19 ゼネカ・リミテッド ペプチド誘導体
AU739130B2 (en) 1996-06-11 2001-10-04 Northern Sydney And Central Coast Area Health Service T cell antigen receptor peptides
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
EP1044019A1 (fr) * 1998-01-09 2000-10-18 Circassia Limited Procedes et compositions de desensibilisation
AU766498B2 (en) 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) * 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP1128839A4 (fr) * 1998-11-12 2002-10-09 Yeda Res & Dev Compositions pharmaceutiques comprenant des copolymeres de peptides synthetiques et methodes de prevention et de traitement de la reaction du greffon contre l'hote (gvhd) et de la reaction de l'hote contre le greffon (hvgd)
US7053043B1 (en) 1999-07-23 2006-05-30 Yeda Research And Development Co.Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (fr) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
ATE475883T1 (de) 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
US20060024334A1 (en) * 2001-12-05 2006-02-02 Mark Larche Immunotherapeutic methods and systems
GB2440529B (en) * 2006-08-03 2009-05-13 Proimmune Ltd MHC Oligomer, Components Therof, And Methods Of Making The Same
CN110801013B (zh) * 2019-11-19 2023-03-31 西北农林科技大学 一种生物化学法制备非过敏生漆或漆酚的方法及其产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428965A (en) * 1979-05-31 1984-01-31 The University Of Mississippi Tolerizing and desensitizing compounds, compositions and methods of treatment against dermatological conditions caused by allergens from plants and trees of the Anacardiaceae and Ginkgoaceae families
JPH06506056A (ja) * 1990-10-30 1994-07-07 イミュロジック　ファーマシューティカル　コーポレイション Ｍｈｃ抗原によるペプチド結合検定法
WO1992011859A1 (fr) * 1991-01-08 1992-07-23 Immulogic Pharmaceutical Corporation Hyposensibilisation induite par un peptide de la reponse des lymphocytes t humains a des dermatophagoides (dermatophagoides pteronyssimus)

Also Published As

Publication number Publication date
CA2186873A1 (fr) 1995-10-12
WO1995026980A2 (fr) 1995-10-12
WO1995026980A3 (fr) 1995-12-07

Similar Documents

Publication Publication Date Title
AU2238395A (en) Haptenated peptides and uses thereof
US20240207379A1 (en) Strategies to prevent and/or treat immune responses to soluble allofactors
JP3926839B2 (ja) 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US5824315A (en) Binding affinity of antigenic peptides for MHC molecules
US5804201A (en) Immunomodulatory peptides of vespid antigen 5
JP7102430B2 (ja) 糖尿病の治療のためのペプチド及び方法
HU229489B1 (hu) Tolerogén peptidek
CA2167730A1 (fr) Peptides synthetiques de type mucine et analogues, renfermant des sequences repetees et multiples d'acides amines; leur utilisation
EP0304279B1 (fr) Déterminant peptidique associé à l'immunité
WO1994026774A1 (fr) Nouveaux traitements de maladies allergiques
US20030175285A1 (en) Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
AU3662993A (en) Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens
AU670024B2 (en) Methods of treating or preventing autoimmune uveoretinitis in mammals
AU1582797A (en) Induction of immune response against desired determinants
MXPA04007510A (es) Peptidos tolerogenicos de la proteina basica de mielina.
Curicio‐Vonlanthen et al. Molecular parameters in melittin immunogenicity
EP0783524B1 (fr) Peptides et compositions pharmaceutiques les contenant
Vandenbark et al. Determinants of human myelin basic protein that induce encephalitogenic T cells in Lewis rats.
JP2010235607A (ja) 自己免疫疾患の診断薬と治療薬となるペプチド類
WO1992011859A1 (fr) Hyposensibilisation induite par un peptide de la reponse des lymphocytes t humains a des dermatophagoides (dermatophagoides pteronyssimus)
WO1996010415A1 (fr) Preparations de complexes peptide/systeme majeur d'histocompatibilite
WO1996003106A2 (fr) Peptides d'allergenes derives de poa pratensis
MXPA98007512A (en) Peptides with increased affinity by molecules from locus to leucocitus huma